Optimal medical therapy

ApprovedSmall molecule

Optimal medical therapy is one of 152 small molecule programs targeting Renal artery stenosis. It is currently in Approved.

Indications

Total Trials

Active Trials

151

Competitors

Pipeline

Status by Indication[3][1]

Indication

Renal Artery StenosisActive, not recruiting

Mitral RegurgitationActive, not recruiting

HematomaActive, not recruiting

Myocardial InfarctionActive, not recruiting

Congestive Heart FailureActive, not recruiting

Heart FailureActive, not recruiting

Angina Pectoris, VariantRecruiting

Coronary Artery Disease (CAD)Not yet recruiting

Tricuspid Valve RegurgitationRecruiting

Tricuspid Valve DiseaseNot yet recruiting

Renal Artery StenosisApproved

Active, not recruiting

Mitral RegurgitationPreclinical

Active, not recruiting

HematomaPreclinical

Active, not recruiting

Myocardial InfarctionPreclinical

Active, not recruiting

Congestive Heart FailurePhase 3

Active, not recruiting

Heart FailurePreclinical

Active, not recruiting

Angina Pectoris, VariantApproved

Recruiting

Coronary Artery Disease (CAD)Preclinical

Not yet recruiting

Tricuspid Valve RegurgitationPreclinical

Recruiting

Tricuspid Valve DiseasePreclinical

Not yet recruiting

Showing 10 of 11 indications

Competition

Competitive Landscape

687 competitors in Heart Failure

#DrugCompanyPhaseTrials

Optimal medical therapy

HHelios Health Institute GmbH

Approved

2 2

Bayer Aspirin

Bayer

Preclinical

2 3

Amidate

Pfizer

Preclinical

1 4

Brethine

Sanofi

Preclinical

1 5

Medrol

Pfizer

Preclinical

1 6

LCZ696

Novartis

Preclinical

15 7

Monoferric

PPharmacosmos A/S

Preclinical

5 8

Savaysa

Daiichi Sankyo

Preclinical

—9

Bystolic

VVitae Pharmaceuticals Inc., an Allergan affiliate

Preclinical

4 10

Activase

Roche

Preclinical

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2027

N/ARecruiting

Myocardial Infarction

NCT05665608

Q3 2028

PreclinicalRecruiting

Tricuspid Valve Regurgitation

NCT07691307

Q4 2029

PreclinicalNot yet recruiting

Coronary Artery Disease (CAD)

NCT07678021

Q2 2030

N/AActive, not recruiting

Trial

NCT04482062

Clinical

Trials by Indication[1]

Trial2 trials

A Trial in Stable Intermediate Coronary Lesions and Grey-zone FFR Values

Completed·GGolden Jubilee National Hospital·N/A·NCT02425969·108 enrolled

TRISCEND II Pivotal Trial

Active, not recruiting·EEdwards Lifesciences·N/A·NCT04482062·864 enrolled

Heart Failure2 trials

Cardiac Contractility Modulation (CCM) Therapy in Subjects With Medically Refractory Heart Failure

Terminated·IImpulse Dynamics·N/A·NCT02857309·50 enrolled

Dobutamine Echocardiography In Patients With Ischemic Heart Failure Evaluated for Revascularization

Completed·MMedstar Health Research Institute·N/A·NCT00074724·319 enrolled

Chronic Total Occlusion2 trials

Drug-Eluting Stent Implantation Versus Optimal Medical Treatment in Patients With Chronic Total Occlusion (DECISION-CTO)

Terminated·SSeung-Jung Park·Phase 4·NCT01078051·840 enrolled

Randomized Comparison of Optimal Medical Therapy and Percutaneous Recanalization for Chronic Total Occlusion (COMET-CTO)

Completed·CClinical Centre of Serbia·Phase 4·NCT02964975·100 enrolled

Sudden Cardiac Death2 trials

Personalised Risk scOre For Implantation of Defibrillators in Patients With Reduced LVEF≤35% and a Low Risk for Sudden Cardiac Death

Withdrawn·HHelios Health Institute GmbH·N/A·NCT04540354

Personalised Risk scOre For Implantation of Defibrillators in Patients With Preserved LVEF>35% and a High Risk for Sudden Cardiac Death

Withdrawn·HHelios Health Institute GmbH·N/A·NCT04540289

Hematoma1 trial

EndovaScular Versus mediCaL mAnagement of Uncomplicated Type B Intramural heMatoma Trial (ESCLAIM)

Unknown status·GGuangdong Provincial People's Hospital·N/A·NCT04808661·154 enrolled

12 more indications

Heart Transplant1 trial

Assessment of Revascularization Versus Conservative Treatment in Heart Transplant Patients for a Clinical Event Reduction

Terminated·AAssistance Publique - Hôpitaux de Paris·Phase 3·NCT01795729·6 enrolled

Survival1 trial

The Role of Willingness of Participation in Cardiology Trials on the Survival of Patients

Unknown status·SSemmelweis University Heart and Vascular Center··NCT03840499·400 enrolled

Mitral regurgitation1 trial

Evaluation of Outcomes of CRT and MitraClip for Treatment of Low Ejection Fraction and Functional Mitral Regurgitation in HF

Withdrawn·MMontreal Heart Institute·N/A·NCT02985268

Renal artery stenosis1 trial

Medical and Endovascular Treatment of Atherosclerotic Renal Artery Stenosis (METRAS Study)

Unknown status·UUniversity Hospital Padova·Phase 4·NCT01208714·60 enrolled

Congestive Heart Failure1 trial

Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure

Terminated·—·Phase 3·NCT00608140·2 enrolled

Myocardial Infarction1 trial

Prevention Of Sudden Cardiac Death After Myocardial Infarction by Defibrillator Implantation

Recruiting·—·N/A·NCT05665608·3,595 enrolled

Tricuspid Valve Disease1 trial

A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation.

Not yet recruiting·PP+F Products + Features USA Inc.·Preclinical·NCT06458907·780 enrolled

Tricuspid Valve Regurgitation1 trial

A Prospective, Multicenter, Randomized Controlled Clinical Trial Protocol Evaluating the Safety and Efficacy of the TruGamma Transcatheter Tricuspid Valve System in Patients With Severe Tricuspid Regurgitation

Recruiting·JJiangsu Trulive Medical Co., Ltd·Preclinical·NCT07691307·180 enrolled

Tricuspid Regurgitation1 trial

A Prospective, Multicenter, Randomized, Controlled Pivotal Trial to Evaluate the Safety and Effectiveness of Transcatheter Tricuspid Valve Repair With the Edwards PASCAL Transcatheter Valve Repair System and Optimal Medical Therapy (OMT) Compared to OMT Alone in Patients With Tricuspid Regurgitation

Recruiting·EEdwards Lifesciences·Preclinical·NCT04097145·1,270 enrolled

Coronary Artery Disease (CAD)1 trial

Micro-axial Flow Pump-Supported PCI Plus Optimal Medical Therapy Versus Optimal Medical Therapy Alone in Complex Coronary Artery Disease With Ischemic LV Dysfunction: A Prospective, Multicenter, Randomized Controlled Trial

Not yet recruiting·CChina National Center for Cardiovascular Diseases·Preclinical·NCT07678021·452 enrolled

Angina Pectoris, Variant1 trial

Implantable Cardioverter Defibrillator Versus Optimal Medical Therapy In Patients With Variant Angina Manifesting as Aborted Sudden Cardiac Death

Recruiting·KKee-joon Choi·Approved·NCT02845531·140 enrolled

Unspecified1 trial

Electrophysiological Effects of Late PCI After MI

Completed·UUniversity of Maryland, Baltimore·N/A·NCT00119847·300 enrolled

Sources

References

[1]
ClinicalTrials.gov — 21 trial records for Optimal medical therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Optimal medical therapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Optimal medical therapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Helios Health Institute GmbH company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Approved[1]
Company: HHelios Health Institute GmbH

Optimal medical therapy

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2027

Q3 2028

Q4 2029

Q2 2030

Trials by Indication[1]

Trial2 trials

Heart Failure2 trials

Chronic Total Occlusion2 trials

Sudden Cardiac Death2 trials

Hematoma1 trial

Heart Transplant1 trial

Survival1 trial

Mitral regurgitation1 trial

Renal artery stenosis1 trial

Congestive Heart Failure1 trial

Myocardial Infarction1 trial

Tricuspid Valve Disease1 trial

Tricuspid Valve Regurgitation1 trial

Tricuspid Regurgitation1 trial

Coronary Artery Disease (CAD)1 trial

Angina Pectoris, Variant1 trial

Unspecified1 trial

References

Drug Info

Quick Facts

Related News